Citigroup Issues Pessimistic Forecast for Privia Health Group (NASDAQ:PRVA) Stock Price

Privia Health Group (NASDAQ:PRVA) had its price objective reduced by equities research analysts at Citigroup from $34.00 to $32.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Citigroup’s target price indicates a potential upside of 34.62% from the company’s previous close.

Other analysts also recently issued reports about the stock. Citizens Jmp increased their price target on shares of Privia Health Group from $30.00 to $31.00 and gave the company a “market outperform” rating in a research report on Friday, November 7th. Wolfe Research set a $31.00 target price on shares of Privia Health Group in a research note on Tuesday, January 6th. Stephens reiterated an “overweight” rating and issued a $32.00 target price on shares of Privia Health Group in a report on Thursday, December 4th. Weiss Ratings reissued a “hold (c)” rating on shares of Privia Health Group in a report on Monday, December 29th. Finally, Royal Bank Of Canada assumed coverage on shares of Privia Health Group in a research report on Friday, January 9th. They issued an “outperform” rating and a $31.00 price objective for the company. Thirteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Privia Health Group currently has a consensus rating of “Moderate Buy” and an average price target of $31.00.

Privia Health Group Price Performance

Shares of Privia Health Group stock traded down $0.27 on Tuesday, hitting $23.77. 371,793 shares of the company’s stock traded hands, compared to its average volume of 802,751. The firm’s 50-day moving average price is $23.07 and its two-hundred day moving average price is $23.52. The stock has a market capitalization of $2.92 billion, a PE ratio of 139.82, a price-to-earnings-growth ratio of 1.59 and a beta of 0.83. Privia Health Group has a one year low of $18.77 and a one year high of $26.51.

Privia Health Group (NASDAQ:PRVA) last announced its quarterly earnings data on Thursday, February 26th. The company reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.21. Privia Health Group had a return on equity of 3.06% and a net margin of 1.08%.The business had revenue of $541.17 million during the quarter, compared to analysts’ expectations of $516.61 million. During the same period in the previous year, the firm earned $0.21 earnings per share. The firm’s quarterly revenue was up 17.4% compared to the same quarter last year. On average, analysts forecast that Privia Health Group will post 0.14 earnings per share for the current fiscal year.

Insider Buying and Selling at Privia Health Group

In other Privia Health Group news, CFO David Mountcastle sold 7,697 shares of the stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $25.05, for a total transaction of $192,809.85. Following the completion of the transaction, the chief financial officer owned 172,909 shares in the company, valued at approximately $4,331,370.45. This represents a 4.26% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Matthew Shawn Morris sold 16,550 shares of Privia Health Group stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $25.00, for a total value of $413,750.00. Following the completion of the sale, the director directly owned 68,188 shares in the company, valued at $1,704,700. This represents a 19.53% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 74,930 shares of company stock worth $1,874,410 over the last ninety days. 10.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Privia Health Group

Several institutional investors have recently bought and sold shares of PRVA. Hantz Financial Services Inc. grew its stake in shares of Privia Health Group by 456.2% during the 4th quarter. Hantz Financial Services Inc. now owns 1,129 shares of the company’s stock worth $27,000 after acquiring an additional 926 shares in the last quarter. Global Retirement Partners LLC boosted its holdings in Privia Health Group by 579.8% during the fourth quarter. Global Retirement Partners LLC now owns 1,584 shares of the company’s stock worth $38,000 after purchasing an additional 1,351 shares during the last quarter. Canada Pension Plan Investment Board grew its position in Privia Health Group by 48.0% in the second quarter. Canada Pension Plan Investment Board now owns 3,700 shares of the company’s stock valued at $85,000 after purchasing an additional 1,200 shares in the last quarter. Kestra Advisory Services LLC bought a new position in Privia Health Group in the fourth quarter valued at $93,000. Finally, GAMMA Investing LLC increased its stake in Privia Health Group by 198.5% in the 4th quarter. GAMMA Investing LLC now owns 4,314 shares of the company’s stock valued at $102,000 after buying an additional 2,869 shares during the last quarter. Institutional investors own 94.48% of the company’s stock.

Key Stories Impacting Privia Health Group

Here are the key news stories impacting Privia Health Group this week:

• Positive Sentiment: Analyst upgrade/target increase — Truist raised its price target on PRVA from $31 to $33 and maintained a Buy rating, signaling analyst confidence in growth and providing a visible upside case that can attract buyers. Read More.
• Positive Sentiment: Strategic acquisition — Privia is acquiring Evolent’s ACO business to expand its value‑based care scale; investors often view deals that grow managed‑care revenue and ACO scale as margin‑accretive long term if integration succeeds. Read More.
• Positive Sentiment: Clinical/outcomes win — A Privia‑led colorectal cancer screening program (with Exact Sciences and Amalgam Rx) achieved an 84% screening rate per a case study, supporting Privia’s quality metrics and value‑based care narrative that can help contract negotiations and reimbursement. Read More.
• Positive Sentiment: Recent fundamentals — Privia reported a strong quarter on Feb. 26 (EPS and revenue above consensus; revenue +17.4% y/y), which underpins the bullish analyst activity and higher valuations from investors focusing on growth. Read More.
• Neutral Sentiment: Strong institutional ownership — Large institutional buys and concentrated ownership (over 90% institutional) can amplify moves in either direction but also provide a steady shareholder base; this is background context rather than an immediate catalyst. Read More.
• Negative Sentiment: Insider selling — Director Matthew Shawn Morris sold ~24,338 shares across Feb. 26–27 and CFO David Mountcastle sold ~13,058 shares across Feb. 26–27. Senior insider sales can create short‑term downward pressure and raise questions for sentiment, even though both retain significant holdings. Read More. Read More.

About Privia Health Group

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.